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Bone histomorphometry comparison between patients on maintenance
dialysis with and without hyperalumineinia. C/i. Noel, iL. Sebert, A.
Marie, B. (iosselin, fL. Dhondt, V. Jacqoet, V. Dumur, P. Leflon, P.
Itforiniere, !i4. Dracon, .1. Gueuis, G. Leliei're. A. Fournier, A. Tacquei.
HOpital Ca/me/ic 59000 Life, C.H. U. D'Amiens 80000 Amien.c, and
Hipital Larihoisiere, Paris, France. in order to define the aluminium
(Al) toxicity on bone, two groups of hemodialyzed patients were
compared. Group I : patients on maintence hemodialysis (at the hospi-
tal) treated by Al hydroxide containing phosphate binders and whose
serum Al levels were >100 sg/litcr for at least one year. Group 11: 10
patients on hernofiltration treated by calcium carbonate and whose
serum Al levels were <30 jsg/liter. None of these patients had evident
radiographic sign of osteitis fibrosa. The two groups were matched in
regard to age, sex and renal failure etiology, hut not in regard to
duration of dialysis. According to parameters related to Al accumula-
tion, the two groups were well differentiated: mean serum Al concen-
tration was 163.6 jzg/liter (±57.7) in Group I and .8 (4.2) in Group 11
(1' < 0.001). Net change of serum Al concentration after desferioxamine
test was 177.8 (± 7.8) in Group I and 23.1 (>15.8) in Group II (P <
0.001). Bone Al content was 39.9 pg/liter (+5.5) in Group I and 9.4
(±2.9) in Group Ii (P < 0.001). On the contrary, no difference was
found between Groups I and 11 when bone histomorphometric param-
eters were considered (osteoclast surface, osteoclast/mm2, osteoblast
surface, osteoid surface, osteoid volume, mean osteoid seam thickness.
fractionnal labeled surface, appositional rate, bone formation rate).
Consequently, the observed bone lesions cannot be explained solely by
Al toxicity.
TINU Syndrome: Report of three observations. C/i. Noel, M. I)racori,
fL. D/iondt, G. Lelierre, B. Gosse/in, V. Jacquet, ('unique
J\'i'p/iro/ogiqie, Höpital Calmetie, !,ille, France. Acute renal failure
due to tubulo-interstitial nephritis accompanied by uveitis has been
observed in three young women (TIN!,) syndrome). In all these three
cases, the nephropathy was preceded (one to three months) by
as(hcnia, anorexia, weight loss, and a major inflammatory syndrome.
Nonsteroid anti-inflammatory drug (NIAS) consumption was noted. tn
two cases, uveitis appeared after the nephropathy had subsided. Renal
biopsies pert'orrned in the three patients revealed lesions mainly of the
interstitium with mononuclear cell infiltration; immunofluorescence
studies were negative. Although the severity of ncphropathy was
variable, the renal function recovered completely, returning to normal
within two, three, and 24 months on corticosteroid therapy. The TINU
syndrome is a rare situation compared to the frequent acute interstitial
nephritis due to NIAS. however, the real incidence of this syndrome
might be underestimated since uveitis can appear few weeks later and
its origin not be related to the nephropathy episode,
Alterations in renal hemodynamics and function with converting en-
i.yme inhibition in kindey transplant recipients. U. Liourad, J. Rib,ctein,
A. Argues, A. )Wimran, C. Mion, Di,'i.sion of fVephrologv, Höpila/
Lapevronie, Monipel/ier Unirersitv hospital, Mon/pci/icr, France. The
activation of the renin—angiotensin system (RAS) is thought to he an
important factor contributing to post-transplantation (Tx) hypertension(HT) and a major mechanism in case of renal artery stcnosis. We
investigated the acute effects on mean arterial pressure (MAP), effec-
tive renal plasma flow (ERPF), glomerular filtration rate (GFR. in
ml/miu/1.73 mi), and electrolyte excretion rates of angiotensin—
converting—enzyme inhibition (CEI) by captopril in 21 HT and nine
normotensive (NT) renal transplant recipients. Patients with confirmed
artery stenosis were excluded. CEI incuded in both HT and NT a
decrease in MAP (—8 I and —3 1 mm Fig, respectively) and in
tiltration fraction (FF = —0.07 0.02 and —0.06 0.02), whereas
ERPF and GFR were not significantly affected. A significant decrease in
renal resistance was observed only among lIT. Urinary Na excretion
rate increased in both NT and HI. Changes in MAP (r — 0.66), ERPF(r ' 0.74) and FF (r —0.88) were correlated with the log of control
PRA. HT patients could he divided according to the change in ERPF
into two subgroups: SQ positive (% change ;> 20%; N 10) and SQ
negative (% change ranging from —30 to +5%: N — II).
SQ positive SQ negative
Control CE! P Control CEI P
MAP 119±2 108±2 c;d 116±3 111±2 b
ERPF 220 12 320 24 c;e 385 29 344 27 C
GFR 73 2 72 7 a;e 101 7 83 6 c
(CE! vs. C = a:NS; b:P < 0.05; c:P < 0.01; SQ pos vs. SQ neg:
d:NS; e:P < 0.0!)
l'RA and serum aldosterone levels were higher in the SQ pos group
suggesting angiotensin production by the native kidneys. These results
prove that RAS participates in the regulation of the renal vascular tone
in transplant patients. In group SQ pos patients, where renal vasocon-
striction was associated with RAS activation and reversed with CEI,
long—term (12l appears to he the treatment of choice.
Effect of a high protein intake on the Na-K.ATPase activity in the thick
ascending limb of henle's loop. N. Boob, J. Chaven, MM.
Trinh—Trang—Tan, L. Ban/dr. INSERM Unii 90. HipiiaI Necker,
75743 Paris Ceder /5, France and Kennedy Inst it ole of Rheumatology,
London WO, United Kingdom. We previously reported that the kidney
hypertrophy induced by high protein diet is characterized by a marked
increase in thickness of the inner stripe of the outer medulla, and,
within tlus zone, by a selective hypertrophy of the thick ascending limb
(TAI.) of Henle's loop. The TAI. is the nephron segment responsible
for the "initial effect" of the urine concentrating mechanism. Since high
protein diet is known to increase urine concentrating ability, it may he
assumed that the selective hypertrophy of the TAL is an adaptation
linked to enhanced salt transport in this segment. Na-K-ATPase being
involved in this transport, its activity should thus be increased by high
protein diet. To test this hypothesis, we measured the TAL diairieter
and Na-K-ATI'ase activity on kidney sections from rats fed isocalorie
amounts of low (LP. N = 5) or high (HP, N 5) protein diet (10% and
32% casein, respectively) far four weeks. Our results confirm the
increase in I'AL diameter, leading to a twofold larger volume of
epithelium per unit tubular length in HP than in VP. Na-K-ATPase
activity was measured in presence of dillereni. ATP concentrations (Ito
30 nM) by cytochemistry and microdensitometry. For non-limiting
substrate concentrations (APT tO mM), the Na-K-ATPase activity
expressed per unit tubular volume is similar in both groups of rats (HP:
97 12, VP: 87 9 nmoles P04/mm1. IS mm incubation). However,
when expressed per unit tubular length, this activity is significantly
higher in HP than in I.P rats (802 99 vs .379 41 pmotes P04/mm. IS
mm incubation, respectively; P . 0.01). These results show that high
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protein diet does increase Na-K-ATPase activity in TAL, thus permit-
ting enhanced active NaC1 transport in this segment. Comparison of
enzyme measurements with morphometric measurements suggests that
this increase in transport capacity is not due to an increase in density
but to an increase in number of enzymatic units in relation to the TAL
cell hypertrophy.
Pharmacokinetics of prednisolone in children with nephrotic syndrome.
S. Baron, M.C. Raux—Demay, D. Vasmant, A. Bensman, Unite de
Néphrologie Pediatrique et laboratoire d'endocrinologie, Hôpital
Trousseau, Paris, France. In nephrotic syndrome (NS) the response
and tolerance to corticotherapy is variable. The aim of this work was to
study the relationship between the pharmacokinetic parameters (PKT)
and the major clinical parameters of Prednisolone (Plo), that is, thera-
peutic effectiveness, required dosage, duration of remissions, and the
tolerance measured according to the results of a score. The serum Plo
levels were measured using a binding assay after administering oral
Prednisone (1 mg/kg) to 16 children undergoing corticotherapy for NS.
Hepatic and renal functions of all the patients were normal. They were
not receiving any other medication which might induce a variation in
the metabolism of the Plo. PKT differed greatly : Plo peaks 1.2 to 6.1
rg/ml; peak interval 30 to 120 mn; A (slope of a log—linear plot of plasma
concentration vs. time) from —ito —8.9 x lO- mm; halftime (Tl/2)
77 to 848 mn; area under the time—concentration curve (AUC) = 416
to 1353 g/ml x nm. The children were divided into groups according
to: (1°) time required to obtain remission; within two weeks (N = 4) or
more than two weeks (N 12); (2°) dosage necessary to obtain
remission: usual dosage 2 mg/kg day (N = 9) or high dosage therapy (N
= 5); (3°) total amount of steroids required to maintain remission: low
amount (N = 7) high amount (N = 7). The PKT values were similar in
each group. A low serum albumin level (< 25 g/liter) did not affect PKT.
The peak values, A, and T 1/2 were not different in children who fit the
criteria of low tolerance and those who tolerated corticotherapy well.
AUC values (which reflect the bioavailability) were markedly elevated
(P < 0.05) within the low tolerance group. In conclusion, the variability
of the effectiveness of corticotherapy is independent on the PKT. The
variability in the tolerance could be accounted for by a difference in the
bioavailability of the drug.
Enhancement of glomerular procoagulant activity (PCA) and fibrin
deposition during Hg Cl2-induced autoimmune nephritis (Hg CI2GN) in
the rat. A. Kanfer, D. de Pros!, D. Nochy, C. Guettier, V. LeFloch, P.
Druet, Service de NEphrologie and INSERM U.294, Hopital Bichat
and INSERM (1.28, Hopital Broussais, Paris, France. At its acme,
about 20 days after starting the intoxication, Hg Cl2 GN in the Brown
Norway (BN) rat is characterized by gross proteinuria and by the onset
of glomerular fibrin deposits of uncertain pathogenesis. Therefore we
investigated, at different phases of this experimental disease, changes in
the tissue factor (TF)-like PCA produced by isolated glomeruli. BN rats
were subcutaneously injected with 100 g Hg Cl2/lOOg body weight on
alternate days; paired control rats were injected with water. At days 12,
20, 32 and 42 after starting Hg Cl2 injections, the following parameters
were measured: (a) proteinuria (b) glomerular fibrin deposits semiquan-
titatively assessed by immunofluorescence (c) PCA (TF units/b3
glomeruli) of glomeruli isolated by sieving and mechanically disrupted.
Glomerular PCA increased during the course of Hg Cl2 GN; PCA,
proteinuria and fibrin deposits reached their maximum concomitantly.
Table indicates the observed values (A 5EM):
Day of sacrifice LPCA Proteinuria Fibrin deposits
l2(N=6)
20 (N = 11)
32(N = 7)
42(N=5)
% of controls (mg/24hr)
0
+
+25±16
+206 73
+60 28
+10±23
a P < 0.01 v
2±1117 l7
52 l2
67±22
s controls
Conclusion: during Hg Cl2 GN in the BN rat, the synthesis of glomer-
ular PCA is enhanced; this result suggests that glomerular PCA might
be involved in the local fibrin formation.
Circadian variations in the urinary excretion of three tubular brush
border enzymes in rats. J.C. Cal, F. Letnoigne, R. Crockett, J. Cambar,
Groupe d'Etude de Physiologic et Physiopathologie Rénales, and
Laboratoire de Biochimie, Faculté de Pharmacie, Bordeaux, France.
This study was designed to investigate the circadian periodicity in the
urinary activity of three brush border enzymes of renal tubular origin,
considered as sensitive markers of nephrotoxicity, gamma glutamyl-
transpeptidase (GGT), leucin aminopeptidase (LAP), and alkaline phos-
phatase (AP). The urine of 15 male Wistar rats housed singly in
metabolism cages in temperature— and humidity—controlled quarters
and standardized to an LD 12 hrs illumination schedule (light from 08 hr
to 20 hr), was collected at four hour intervals during 24 hours. Enzyme
activity was assayed by colorimetric and automatic procedures with a
Beckman TR. The results were analyzed by the cosinor method, fitting
a cosine curve to the data using the method of least squares. The
urinary excretion of these enzymes (expressed in IU per mmoles
creatinine) exhibited statistically significant circadian variations: from
59.9 16.2 at the end of the dark span to 144.7 21.2 (P < 0.001) at
the end of the light span for GGT; from 2.76 0.63 between 04:00 and
08:00 to 5.54 0.87 between 16:00 and 20:00 (P < 0.001) for LAP; and
from 3.92 0.57 between 08:00 and 12:00 to 16.86 3.37 between 16:00
and 20:00 (P < 0.001) for AP. Circadian rhythms in the urinary activity
of the three enzymes were statistically validated and quantified by the
cosinor method. Their parameters are very similar: large amplitude
(GGT: 52%, LAP: 45%, AP: 38%) and acrophase occurring at the end
of the rest span (GGT: 17:30 00:45, LAP: 17:00 01:00, PAL: 19:50
01:00). Such findings, consistent with the circadian variations of GOT
in kidney homogenates thus reflect a periodicity in renal tubular
function. Its acrophase occurs at the end of the light phase, contrary to
that of the glomerulus function which occurs at the end of the dark
phase.
Decreased expression of C3b receptor (CR1) on erythrocytes of patients
with systemic lupus erythematosus (SLE) contrasts with its normal
expression in other systemic diseases and does not correlate with the
occurrence or severity of SLE nephritis. M.H. Jouvin, M.D.
Kazatchkine, INSERM U28, Hôpital Broussais, Paris, France. Expres-
sion of CR1 on erythrocytes is decreased in patients with SLE and the
CR1 antigen is absent from podocytes in severe diffuse proliferative
nephritis of SLE. The number of CR1 per erythrocyte (CRI/E) was
measured with a radiolabeled antibody. Among 112 lupus patients
studied in France, the number of CRI/E was 62% of the mean for normal
individuals (P < 0.001). No correlation was found between CR1 number
on erythrocytes and the presence or immunohistopathological type of
glomerulonephritis. The number of CRI/E of 30 patients with non-SLE
nephritis (idiopathic rapidly progressive glomerulonephritis, Goodpas-
ture's syndrome, Wegener syndrome, minimal change nephrotic syn-
drome, membranous glomerulonephritis, membranoproliferative gb-
merulonephritis, Henoch—SchOnlein purpura, Berger's disease, focal
hyalinosis, acute post-infectious glomerulonephritis, diabetic nodular
glomerulosclerosis, amyloidosis, periarteritis nodosa) was slightly de-
creased (89% of the normal mean, P < 0.025), which could not be
attributed to glomerular immune complex deposits or vasculitis. In
contrast, the number of CRI/E was not decreased in patients having
rheumatoid arthritis, scleroderma, Sjogren ' s syndrome, mixed connec-
tive tissue disease, and dermatopolymyositis.
Urinary sediment analysis and lupus nephritis. M. Laville, Ph. Michel,
H. Pellet, P. Zech, J. Traeger, Clinique de Néphrologie et Maladies
Métaboliques, pavilion P, Hdpital Edouard—Herriot, Lyon, France. We
studied the correlation between the results of the urinary sediment (US)
analysis and the clinical or biological criteria of systemic lupus
erythematosus (SLE). US anomalies were evaluated 64 times in 26
patients (22 females, four males) whose average age was 26. The
average interval between the SLE diagnosis and the first US analysis
was 6.3 years. Out of 64 US, 63 had a detailed clinical evaluation of the
LED visceral lesions (evaluated by clinical examination, proteinuria,
hematuria and creatininemia) and 56 US had laboratory evaluation of
anti-DNA antibodies (circulating immune complex levels and comple-
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ment levels) made on the very same day. In 10 cases a renal biospy was
done on the same day as the [IS. According to the nnmher of
erythrocytes and casts in the orine and according to the presence of
lymphocytes and lipids, fonr (0, 1, 2, 3) cytological degrees of glomer-
ular involvement were defined. At the same time, according to the
clinical and hiological data, foor levels of lupus activity (0. I, 2, 3) were
also established. Elevated cytological scores are correlated with the
severity of biological activity; for instance, the 3 scored glomerular
cytology fonnd in 83.3% of eases corresponds to the third biological
activity degree. A normal US was fonnd in the ease of histological
minimal changes lesions and score 3 was fonnd when the histology
showed cellular proliferation (membranoproliferative ON, extraeapil-
lary ON). No correlation was fonod between the clinical activity and
the US. The evolntion of lupus nephritis can be forecast on the basis of
the US. in two patients four successive US were made, and a
correlation was found between the evolution of the glonierular score
and the biological and clinical evolution of the lupus nephritis. in
conclusion. US analysis is a good method to evaluate the severity of the
disease.
l)oes portal hypertension play a role in IgA mesangial glomerulone-
phritis (igU ON)? J. Laorent, C. Lagroe, C. Bruoeao, M. Kozand/ian,
Service tie Néphro/ogie. Hopita/ henri Mont/ar, Créteil, France.
Among the factors responsible for tgA ON, the role of hepatie diseases
is well established. However, the role of portal hypertension has not
been investigated. The following ease illustrates this possibility. Mr.
Louis B presented at age 32 with minimal proteinuria (<1 g/24 hrs) and
microscopic hematuria (10,000 to 50,000 RBC/min). At age 4t), protein-
uria >3 mg/24 hrs justified a renal biopsy which revealed a diFfuse
mesangial proliferative ON with IgA deposits. The serum IgA level was
above Sot) mg/l00 ml. There were no clinical signs of hepatie insuffi-
ciency. Treatment of local infections and non-steroidal anti-inflamm-
atory agents were of no effect on proteinuria levels and hematuria, but
renal function and blood pressure remained normal. At age 49, he
presented with hematemesis and melena: gamma-OT levels were 108 IL
ml with a maeroeytosis at 102 t: alcoholic intoxication was admitted.
Esophageal variees were found a porto-eaval anastomosis performed;
the portal pressure was reduced from 30)0 18cm 1120. A pre-operative
liver biopsy showed a discrete steatosis without cirrhosis. After this
intervention, the proteinuria and the hematuria disappeared within a
few days. This clinical cure has been maintained durog a follow up of
six years. The serum ereatinine level and the blood pressure have
remained normal. The serum levels of IgA were unchanged (>800
mg/l00 ml) but gamma-OT and maeroeytosis returned to normal. For
ethical reasons, we have not performed a second renal biopsy. It is thus
impossible to confirm this cure histologically. The clinical course
underlines the major role played by portal hypei-tension. in such eases
of IgA ON, porto-eaval shunts may prevent lgA polymerization in the
liver, a necessary step in the excretion of IgA by the biliary tree. This
excretion may well be decreased in certain liver disease. The occasional
severe outcome of IgA ON could lead in sonic eases to earlier surgery
for portal hypertension or even to surgery in the absence of patent
portal hypertension.
Cyclosporine in steroid—dependent (SD) or steroid—resistant (SR) idio-
pathic nephrotic syndrome (INS): Preliminary results. U. Lagrae, J.
Laorent, D. Beigli iii, A. Sabel, Service dc Nép/iralagie, Hépital Henri
Mondor, Crétei/, France. In SD INS protacted steroid therapy leads to
complications; in SR INS there are risks of supervening infections,
metabolic disorders and progression to renal failure. Alkylating agents
are sometimes efficient hut later involve severe hematalogie, oneogenic
and gonadie side effects. The immunological perturbations described in
INS prompted an investigation of the effect of Cyclosporine (C) due to
its aseehanism of action. The following protocol was established with
Sandoz Laboratories for this pilot study. Prednisone was continued at
10 mg/day; the starting dose of C was 3 mg/kg/day in one intake in the
morning; it was increased to S mg/kg/day according to plasma C levels,
which were measured once a week, 24 hours after the preceding intake
of C. The scheduled duration of C treatment was three months. We
treated six adults with INS of long evolution (2 to 20 ans); five were SR
(four minimal changes (MC), and one focal glomeruloselerosis (P05))
and one was SI) with high steroid efficacy threshold. Initial proteinuria
was permanently over 6 g/day, with normal renal function and blood
pressure. Decrease in proteinuria occurred within three to six weeks,
and two weeks later disappeared in four cases and was less than 2 g/24
hours in the two other cases (one MC and one P05). Two to six weeks
after the end of treatment, a relapse occurred in all eases, proteinuria
rising rapidly to the pretreatment level. A new C treatment at S
mg/kg/day was followed by disappearance of proteinuria in four eases
and reduction of its level (<2 g/day) in the two other eases, in the same
time interval. C treatment has presently been continued for a duration
of six to nine months (Dee. 85). These results have been achieved with
low C plasma levels, for 25 to 130 ng/ml. without nephrotoxieity
(ereatinine levels, urinary p2-micrnglohulin, enzymuria were un-
changed), or hepatotoxieity; two eases of moderate hypertriehosis and
gingival hyperplasia were noted. in summary, in these eases of SD or
SR INS, without any trend to spontaneous regression, C demonstrated
a short—term favorable influence on the course of the disease, with a low
dosage and a good tolerance. however, we do not know how long this
treatment must be continued and what are the criteria for reducing the
dosage and discontinuing the drrig.
Drug (D)-assoeiated acute renal failure (ARF): A prospective collabo-
rative study of 81 biopsied patients (PTS). Société de Néplo'alagie. I).
Kleinknecht, P. Lam/a/s. B. Ga/dftir/, Centre Haspitaber, Maatreoi/ &
Hop/mi Necker, Paris, France. During a one—year period, D-assoeiated
ARE was recorded in 398 pts registered in 58 Nephrology Units. Of
these, 81 underwent a renal biopsy (RB) (male: 52, fensale: 29; mean
age: 57.3 years, range IS to SI). D involved were primarily non-steroidal
anti-inflammatory drugs (25). antibiotics (22). mainly aminoglyeosides
(14), glafenin (7), contrast media (7), diuretics (4), and other D (16 pts).
RB showed acute tubular necrosis (ATN) in 42 pts, acute interstitial
nephritis (A IN) in 20—including nine with epithclioid granulomas—
underlying chronic nephropathy in 14. minimal changes in 3. mesangi-
olysis in I, and tobular deposits of oxalate in 1. Nonoligurie ARE
occurred in 49 pts, macroscopic hematuria in 9 and heavy proteinuria in
7. Hypersensitivity reactions (fever, arthralgias and/or skin rash plus
suggestive biological and/ar pathological signs) were documented in 28
pts, including 20 with AIN and 6 with ATN. Ten pts died, 48 recovered
fully or regained previous renal function, and 19 retained permanent
renal damage (23.5%), requiring chronic dialysis in I. Comparison
between pts with ATN and those with AIN showed that the latter had
a higher incidence of nonotigurie ARE (73.7% vs. 45.2%, P < 0.02),
clinical signs of hypersensitivity (55% vs. 19%, P < t).01), blood
hypereosinophilia (55% vs. 11.9%, 1' <0.001). a longer duration of the
ARE period (22.2 vs. 10.9 days, P < 0.01), and more often permanent
renal damage (PRD) (60% vs. 21.4%, P 'C 0.01). In conclusion: (I)
D-assoeiated ARE is an underestimated cause of PRD; (2) PRD is more
frequent in pts with MN than in those with ATN: (3) AIN should he
recognized by an early RB, especially in pts with hypersensitivity signs;
(4)the benefit of steroid therapy in AIN remains a challenge. and results
of controlled trials would he helpful to assess its value in preventing this
type of ARE.
Hyponatremia in beer driakers. F. Schillinger. B. Montagnac, F.
Gely, /. Mi/cent, Service tie Népliro/a pie ci t/'HOmac/ialyse, ChIC tie
Trayes, France. The beer drinker's syndrome, first reported in 1971 by
Demanet, seems little known since there are only about twenty obser-
vations in the literature. Mrs. C. Anita, 23-years—old, epileptic, de-
pressed and alcoholic since four years was hospitalized in late 1984 for
disorders of consciousness regarded as post-critical. They are in fact
due to an increase of iotraeellular fluid without clinical signs of
extracellolar dehydration, with (in mmol/liter) Na: 117. Cl: 51, K: 2,1,
RA:52, osniolality: 269. Also present are hemoconeentration (total
protein: 87 g/liter) and renal failure (ereatinine: 601 p.mol/liter) Diuresis
is 1050 ml with (in minol/hiter) Na: 48, K: 14, osmolality: 249. Plasma
level of ADH is normal at 6.5 pg/mI. The correction of these metabolic
disturbances allows fast recovery of consciousness. Owing to the
persistanee of the renal failure (ereatinine clearance: 19 nil/mn) and of
a nonseleetive proteinuria at 2 g/day. a renal biopsy was performed,
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showing severe chronic tubulo-interstitial lesions, whereas pyelography
was normal. Our patient confirms the recent increase of beer intoxica-
tion (about six liters/day), with anorexia and vomiting. Six other
identical episodes occurred during one year because intoxication could
not be stepped despite cures. The beer drinker's syndrome corresponds
to an intracellular fluid increase due to hyponatremia of double etiology;
on the one hand, sodium depletion through low intake, vomiting,
urinary loss (osmotic diuresis and, in our case, chronic tubulo-intersti-
tial nephropathy), and on the other, inadequate compensation by high
osmotic but low—salt drinks, beer containing only I to 5 mmol Na/liter
according to the brand. In fact, the water balance is nearly correct while
the sodium balance becomes progressively negative as beer intake
increases. The responsibility of an inappropriate secretion of ADH can
be eliminated, but a potential natriuretic factor present in beer remains
in discussion.
Relative hypomagnesuria in renal stone formers: Frequency and influ-
ence of oral calcium load. M. Laheeuw, N. Pozet, X. Martin, P. Zech,
Clinic of Nephrology and INSERM U 80, F. Herriot Hospital, Lyon,
France. The magnesium urinary flow rate was studied in 243 renal stone
formers. A fasting relative hypomagnesuria (hypoMg) was observed in
82, being the only urinary abnormality in 21, associated with
hypercalciuria (HC) in 32, hyperuriduria (HU) in 5, and with HC + HU
in 24 cases. In hypoMg and normoMg patients, the frequencies of
females (29.3 vs. 42.2%) and HU (35.4 vs. 30.4%) are similar. HC is
more frequent in hypoMg (68.3 vs. 38.5%, P < 0.01) either fasting HC
(30.5 vs. 14.9%, P < 0.02) or hyperabsorptive HC (37.8 vs. 23.6%, P <
0.10). In none of the HC groups was a difference between hypoMg and
normoMg patients found for blood calcium, magnesium or uric acid,
fasting sodium, and calcium excretion. A 635 mg oral calcium load
disclosed no differences in postload calcium excretion, and the increase
in magnesium excretion is normal both in normo-and hypoMg whatever
the type of HC. Conclusion: relative hypomagnesuria is frequent,
especially in hypercalciuric patients. Nevertheless it is not associated
with any subtype of hypercalciuria and not dependent on an increased
calcium input from the gut. The changes in tubular handling of magne-
sium induced by the calcium load are similar in hypo- and
normomagnesuric stone formers.
Short— and long—term effects of moderate dietary calcium restriction
combined with oxalate restriction on urinary oxalate excretion in calcium
stone formers. P. Jungers, B. Lacour, T. Loubaris, fL. Francais, M.
Bruneau, N. Chopin, M. Daudon, Departments of Nephrology and
Biochemistry, Necker Hospital, and Laboratoire Cristal, Saint—Cloud,
France. As a strict restriction of dietary Ca (400 mg/day) often
increases oxaluria, we prospectively evaluated the short— and
long—term effects of a moderate Ca restriction (MCR, 500 to 600
mg/day) associated with oxalate restriction on daily excretion of Ca
(UaV) and Ox (U0V) and on urine CaOx relative supersaturation
product (RSCaOx) according to Marshall—Robertson in 45 idiopathic Ca
stone formers. They were classified into three groups: normocalciurics
(NC), 18 pts, with U,V <100 mol/kg/day on free diet; diet—sensitive
hypercalciurics (DSH), 4 pts, with UcaV >100 mol/kg/d on free diet
and <75 mo1/kg/d after seven days on MCR; and diet—insensitive
hypercalciurics (DIH), 22 pts with U,V >75 /LmoI/kg/day on MCR.
There was no significant difference between initial values and those
observed after seven days on MCR in any of the three groups with
respect to U0,V, that is (mean Iso) 358 135 to 374 131 mol/day
(NC), 451 140 to 303 168 (DSH), and 425 178 to 357 145 (DIH),
and to RSCaOx, that is, 0.83 0.19 to 0.80 0.24 (NC), 0.92 0.22 to
0.58 0.35 (DSH), and 0.92 0.16 to 0.84 0.15 (DIH). The long—term
effects were evaluated in 33 pts (including seven borderline NC), who
were submitted to MCR, combined to thiazide therapy (TZ) in 25, for
three to 24 months. A significant decrease in Uc,V was observed
between initial and final values in both treatment groups, whereas there
was no increase in U0V, thus resulting in a decreased RSCaOx
(Table).
MCR + TZ (N = 25) MCR alone (N = 8)
initial final initial final
U0V (mo1/ 417 169 356 136 371 157 370 144
day)
UaV (lLmOl/ 127 63 78 25b 98 40 56 31
kg/day)
RSCaOx 0.89 0.19 0.75 0.l8a 0.89 0.17 0.74 0.30
Paired t-test: final vs. initial : a p < 0.02; P <0.001. In conclusion,
in contrast with severe low-Ca diet, MCR (500 to 600 mg/day) either
alone or associated with TZ therapy does not induce an increase in
U0,V or in RSCaOx. Only such moderate Ca restriction should be used
for long—term treatment of Ca stone formers.
A new complication in analgesic nephropathy: The development of a
renal cell carcinoma. W. Lornoy, 1. Becaus, V. Morelle, E. Fonteyne, L.
Thienpont, J. Mesidagh, Department of Nephrology, Urology, Pathol-
ogy, OL Vrouwziekenhuis, Aalst, Belgium. Transitional cell carcinoma
of the renal pelvis and ureter is known to develop more frequently in
patients with prolonged abuse of analgesics containing phenacetin. it
occurred in 8% of our patients with analgesic nephropathy. We ob-
served a renal cell carcinoma in six out of 412 patients with analgesic
nephropathy (1.43%), treated during the last 12 years. They were five
women and one man, mean age 60 years (42 to 75). Only one patient
smoked. The mean serum creatinine was 8.8 mg % (3 to 12 mg %).
Three patients were on regular dialysis treatment. Four patients under-
went a nephrectomy and one patient was inoperable at the time of
diagnosis. Another patient presented with a renal pelvis tumor and a
renal cell carcinoma. The mean tumor size was 5.4 cm (2.5 to 10 cm).
The occurrence of renal cell carcinoma in the general population in the
U.S.A. is 7.5 per 100,000 population per year. Compared with the
general population, the prevalence of renal cell carcinoma in patients
with analgesic nephropathy is highly significant (P < 0.005). In addition,
the male—female ratio in the general population with renal cell carci-
noma is almost 3: 1, while in the present series it is 1:5. After incidence,
rates are adjusted to compensate for the fact that 90% of our patients
with analgesic nephropathy in this series were women, the ratio became
1.8:1. We conclude that patients with analgesic nephropathy have an
increased risk of developing both urothelial tumor and renal cell
carcinoma.
Vasopressin, aldosterone and renin responses to volume depletion and
load in heart transplant recipients. L. Drieu, M. Rainfray, W.
Pruszczynski, C. Cabrol, R. Ardaillou, INSERM 64, Hôpital Tenon and
Department of Cardiac Surgery, Hôpital de Ia Pitié, Paris, France.
Plasma arginine vasopressin (AVP), renin activity (PRA), and aldoster-
one (ALD) were measured immediately before and 60 minutes after
intravenous administration of furosemide and passage from lying to
standing in 10 untreated healthy subjects (group 1), eight asthmatic
patients treated with prednisone (group 2), and 13 heart transplant
recipients treated with prednisone and cyclosporine (group 3). Three
different tests for cardiac vagal innervation were performed in the study
population. They confirmed that the patients of group 3 were denerv-
ated, whereas those of groups I and 2 had an intact cardiac innervation.
Plasma volume depletion after furosemide administration estimated
from the rise in plasma proteins was 10 to 12%. Mean blood pressure
was higher in the transplant recipients but did not change in the three
groups. Heart rate was also greater in the transplant recipients as a
result of vagal denervation. PRA and ALD increased in all the subjects:
2.8, 3.3, and 2.2 times basal value for PRA, 2.7, 4.6, and 2.2 times basal
value for ALD in groups 1, 2, and 3, respectively. In contrast, plasma
AVP increased only in the two control groups (5(1.45 and xl.65 in
groups I and 2, respectively) whereas it was unchanged in the group of
heart transplant recipients (xl.05). AVP responses to an oral water
load (20 mI/kg) and to an intravenous saline load (110.16 M NaCI over
I hr) were also studied in eight and 10 supplementary heart transplant
recipients, respectively. Plasma AVP fell significantly (5(0.76) in paral-
lel with plasma osmolality in response to the water load. In contrast,
plasma AVP was unmodified in response to the saline load whereas
PRA and ALD decreased significantly. These results demonstrate that,
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in hnmans, cardiac receptors and innervation play a dominant i-ole in
AVP, hnt not in PRA and ALD responses to isoosmotic change volnme.
Hemasite5 (HMS): A new connection device for home and/or self
hemodialysis (HHD/SIID). Two years' experience in Langnedoc Roussil-
Ion. iL. FIos'ier, A. ioyeox, B. Canood, C. Chong. C. fVlonrnd, A.
Tliévenet, C. A-lion, Divisions ofCzrdiovoscolor Sorgery and Nephrol—
ogy, Montpellier flniver.sity hospital, France. An excellent hlnod
access is a prereqtnsite for the success of HFID/SHD. Conventional AV
fistula (AVF) remains the gold standard of vascular connection: how-
ever. AVF develops poorly in aboot 25% of patients who are therefore
poor candidates for HHD/SHD. To facilitate the independent treatment
of ESRD patients, the femoral shunt (FS) has been used with success
since 1971) in more than 100 HI) patients, with an actuarial survival of
70% at five years. however, in spite of its advantages, patients with FS
incur a risk of death due to acute hemorrhage from accidental or
voluntary (suicide) ES disconnection. In this context, HMS has been
evaluated as an alternative to k'S in HHD/SHD patients with poorly
developed AVF. From I December 1980 to 30 September 1985, 19 HMS
were implanted in 16 patients (13 M, 3 F, mean age 56 yrs). In five
eases, the prosthesis was directly inserted in an arterialized vein flowing
from an humerobasilic AVF; this model was abandoned because a
fibrous stcnosis of the vein led to thrombosis in about six months in all
eases. Following this negative experience, 14 ElMS inserted on P'IFE
tubings were surgically implanted between the humeral artery and the
axillary vein in 14 patients, with a cumulative experience of 207
patient—months. Complications include two tfirombosis episodes, one
of which was relieved; two exit site infections, easily cured by antibi-
otics; two changes of HMS occluding septum. Twelve of 14 P'I'FE-
ElMS are still functioning for periods ranging from nine to 26 months.
The one—year actuarial survival is 91.3 per cent. Patient acceptance is
excellent. In conclusion, ElMS offers a useful alternative connection for
patients choosing HElD or SHD. The high cost of the prosthesis is
largely compensated for by lower cost of home or self hemodialysis by
comparison with in—center hemodialysis.
Immune response to hepatitis B vaccine in non-dialyzed ureniic pa-
tients. Ph. Chaoveao, T. Lonbaris, AM. CooroocC, B. flefattlinger, J.
Crosnier, P. Jnngers, Departments qf Nephrology and /rnmono-hem-
atology, !Vecker Hospital, and Centre Notional de Transtnsion San.
paine, Paris, France. Imniunc response to HEVAC B vaccine (Institut
Pasteur) was evaluated in 169 uremic pts (100 male, 69 female) whose
vaccination was begun between July. 1982 and June, 1985. Their mean
(± I so) plasma crcatinine (Per) was 543 176 zmol/liter (range: 210 to
1090) and their mean age was 48 t 14 years (range: 18 to 83). Vaccine
schedule included three subcutaneous injections of 5 g each at
monthly intervals (Vi, V2, V3) followed by a fourth injection (V4) two
months later. This was given when no or poor response occurred after
V3 until June 1984, and was routinely given thereafter. Following V3,
the proportion of pts developing anti-lIBs (Ab) titer >3 mlLJ/ml was
59%(l00/l69), including 86 (51%) with Ab titer >10 mlu/ml, defined as
responders (R) whose mean (t 5EM) Ab titer was 199 34 mIU/ml. The
proportion of R(55% vs. 48%)) and their mean Ab titer (214 St vs. 187
46 mW/mI) was higher in females than in males, but the difference is
not statistically significant. The proportion of R significantly decreased
with age, with figures of 81. 44 and 24%, respectively, in age groups
<40, 40 to 59, and >60 years (overall P < 0.0111), but the mean Ab
titer of R did not significantly differ among the three age groups. In the
72 pts who received V4 (mean age: 51 1 13 years, mean Per 535 138
j.rmol/liter, proportion of R increased fi'nm 29/72(40%) to 42/72(65%, P
0.01), that is, a gain in R of 42%, whereas the mean Ab titer of R
increased from 127 49 to 540 1 136 mlU/ml (P < 0.05), (a thur-fold
increase). The proportion of R rose to 85, 67 and 50%, respectively, in
pts aged <40, 40—50 and >60 years (difference V4 vs. V3: P < 0.05 in
pts over 40 years). with an equal rise in Ab titer in the 3 age groups. The
proportion of R following V4 was 72, 65 and 59%, respectively, (with
mean Ab titers of 660 225, 507 243 and 453 218 mtti/ml) in pts
having Per >450, 450—600 and >600 j.tmol/liter at the beginning of
vaccination. Of five pts who did not respond after V4, two became R
after VS. that is, a gain in R of 40%. All 23 pts who received a booster
injection at one year (following V3 or V4) were R except two (who
received V3 without V4). in conclusion, using HEVAC B vaccine,
a protocol involving four subcutaneous injections (and booster injection
at one year), with a fifth injection when needed, may be recommended
in uremic patients and may be expected to afford immune protection to
more than 90% of them. Vaccination should preferably he started
before Per reaches 450 zmol/litcr, especially in older patients.
Carpal tunnel syndrome (CTS) in chronic hemodiaiysis patients. A
criterium for membrane hiocompatihility? S. Lavand, 0. Toopnnce, hi.
Roojonleh, iF. Melin, i. Chanord, Centre hiospitalier et Unii'ersitaire,
Reims, France. Carpal tunnel syndrome is increasingly recognized in
patients undergoing chronic hemodialysis, and amyloid positive
synovitis is sometimes observed. Recently it has been demonstrated
that amyloid was derived from , microglohulin. Although the etiology
of CTS remains obscure, angioacccss—rclatcd chronic edema and ischc-
mic neuropathy are two likely possibilities. An additional causative
factor could be the inadequate hiocompatibility of dialysis membranes.
This membrane effect, if present, could be found in comparing groups of
patients treated since the beginning of dialysis with membranes with
different bioeompatibility. Polyacrylonitrilc (AN 69) membrane and
cuprophane or other ccllulosmc membranes were used. CTS was ob-
served in II patients among the 125 patients presently dialyzed in our
institution. Eight times CTS was bilateral. CTS occurred eight to 14
years after starting dialysis. With this time on hcmodialysis, 13 patients
did not have CTS. The underlying renal disease, age, number of fistula
thromboses did not differ between the two groups. However, patients
with Cl'S were dialyzed for a longer time on ccllulosic membrane (76.7
50.6 months) and a shorter time on AN 69 (48.6 t 37.3 months) than
patients without CTS (21.4 21.2 and 101.1 29.6 months, respec-
tively, P < 0.001). We conclude that time on dialysis is significantly
linked with CTS (Pc 0.001) and that CTS occurrence is associated with
the use nf cuprophanc. CTS in hemodialyzed patients could be partly
prevented by using AN 69 membrane, the polyacrylonitrile membrane
being more permeable to ['12 microglohulin and more biocompatible than
cuprophan membrane.
Articular amyloidosis and flmicroglohulin (/32-M) in long—term
hemodialysis patients. J. Zingrqff, L.H. Noel, P. Beyne, T. Bardin, D.
Droz., M. Touom, M. Uzan, D. Knntz, N.K. Mon. T. Drueke, INSERM
ff90 and Departe,ncnt de NCphrologie, Hópital Neck-er, Service de
Rhnrnatologie, HOpital Lariboisibre, Bard., France. In order to inves-
tigate the particular type of amyloidosis encountered in long—term
hemodialysis patients, we performed in 14 patients a clinical and
histnimmnnological study. Amyloid substance was identified in
synovium, capsula, articular cartilage, and in juxta-articular hone cysts.
All patients were maintained on chronic dialysis for an average of 11.8
years (range 7 to 18 years). None had amyloidosis as pm'imary renal
disease. Ten patients developed a carpal tunnel syndrnmc, seven had
destructive spondylarthropathy. X-rays showed in 12 patients cystic
bone lesions near the hip of the shoulder, five had destructive
arthropathy of the flip and/or the knee. All amyloid deposits were
birefringent in polarized light after Congo red staining and were at least
partly sensitive to pretreatment with potassium pcrmanganate. They
produced a positive immonofisiorescent reaction only with an antm-$2-M
serum and not with the other auti-scra tested. A preliminary biochem-
ical study showed a lower plasma 2-M concentration in dialysis
patients with residual renal function or those regularly dialyzed on
polyacrylonitrile membrane (AN69( (26 and 30.5 mg/liter, respectively)
than in oliguric patients treated on coprophan membranes (mean value
44 mg/liter). Plasma ['12 microglobulin increases during the latter proce-
dure, whereas dialysis with an AN69 membrane tends to decrease the
prediatysis value. Hcmofiltration lowered by half the initial PrM
plasma concentration in the two eases studied. The role of retention
and/or increased biosynthesis of p2-M in the genesis of dialysis related
amyloidosis, and its particular tropism to articular tissues needs further
investigation.
Pharniacokinetics of intraperitoneal Ceftazidime in patients on contin-
ous ambulatory peritoneal dialysis. .J.Ph. Ryckel nck, B. bioranlt de
Ligny, i.M. Batho, M. Vergnaod, Service de NCphrologie CHU
(7cmencean, Cacti, France. 'I'fic pharmacokinetics of intrapcritoncal
Abstracts
Ceftazidime in patients on continuous ambulatory peritoneal dialysis
without (GI) and with peritonitis (G2) have been examined. After six
hours of peritoneal installation of 250 mg of Ceftazidime, the mean
plasma concentrations were 9.27 1.9 (GI) and 13.1 5.65 j.g/ml (02).
The average plasma concentrations over 24 hours were 18.52 4.9 (GI)
and 25.25 6.42 g/ml (G2). Drug peritoneal absorption was similar in
the two groups, 71 8% (01) and 75 7% (G2). Peritoneal clearance
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of Ceftazidime was low, that is, 1.470.43 (GI) and 2.43 1.09 (G2)
mi/mn. Statistical evaluation (Student's test) showed no difference
between 01 and 02. Adequate concentrations of Ceftazidime were
achieved in dialysate to treat peritonitis and plasma levels were
sufficient to treat contingent systemic complications. Ceftazidime pen-
toneal route was a useful treatment of peritonitis in 11 of 13 patients
(85%).
